Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $227.85

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty analysts that are covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among […]

Related Keywords

Michaelw Bonney , ,Needham Company ,Citigroup ,Metlife Investment Management ,Wells Fargo Company ,Securities Exchange Commission ,News Ratings For Alnylam Pharmaceuticals Daily ,Nasdaq ,Alnylam Pharmaceuticals Stock Performance ,Alnylam Pharmaceuticals ,Raymond James Financial Services Advisors Inc ,Alnylam Pharmaceuticals Inc ,Institutional Investors Weigh In On Alnylam Pharmaceuticals ,Great West Life Assurance Co ,Panagora Asset Management Inc ,Dimensional Fund Advisors ,Analyst Recommendations For Alnylam Pharmaceuticals ,Insider Activity At Alnylam Pharmaceuticals ,Get Free Report ,Wells Fargo ,Director Michael ,Exchange Commission ,James Financial Services Advisors ,Life Investment Management ,Asset Management ,West Life Assurance ,Fund Advisors ,Get Free ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Ratings ,Consensus ,